OTC Bulletin Board

S & P Company Insight for HEMOBIOTECH INC
 
 Profile

 
Business Summary: HemoBioTech, Inc. engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Sciences Center (TTUHSC) in Texas. It focuses primarily on the development of HemoTech, an oxygen-carrying solution that performs like red blood cells.
 
Address
  5001 Spring Valley Road
  Suite 1040 - West
  Dallas , TX 75244
  Phone: 972-455-8950
  Fax: 972-455-8951
  Website: http://www.hemobiotech.com
Auditor
  Eisner
  New York
Transfer Agent
  Continental Stock Transfer & Trust Co.
Employees:  5
ShareHolders:  73
Founded:  2001
Domicile:  Delaware
 
  
 
 Background

 
HemoBioTech, Inc., in the development stage as of June 30, 2008, engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Sciences Center (TTUHSC) in Texas. It focuses primarily on the development of HemoTech, an oxygen-carrying solution that performs like red blood cells. The company is headquartered in Dallas, Texas.
History:  INCORPORATED in Delaware Oct. 30, 2003; and on Dec. 1, 2003, merged a Texas corporation of the same name (Predecessor). Predecessor was incorporated in Texas in December 2001.
 
 
 
 
  
 
 Management

 

Management
OfficersPosition
 Arthur P. BollonChairman, President, Chief Executive Officer & Investor Relations Contact
 Ghassan  NinoVice Chairman
 Mark J. RosenblumSecretary & Chief Financial Officer

Directors
 Robert A. Baron
 Arthur P. Bollon
 Robert  Comer
 Bernhard  Mittemeyer
 Ghassan  Nino
 
  
 
 Annual Report

 
Annual Report
 
Income Statement
  20072006
Cost & exps.3,8412,658
Interest income117141
Interest exp.154
Net income(3,275)(2,571)
Share earns. basic($0.22)($0.17)
Share earns. diluted($0.22)($0.17)
 
Balance Sheet
  2007
Assets:
Cash & equiv.2,015
Other curr. assets521
Tot. curr assets2,536
Net property50
Restricted cash55
Total assets2,641
Liabilities:
Accts. pay. & accruals254
Tot. curr. liabs.254
Defr. rent43
Com. stk. p.$0.00119
Paid-in cap.14,186
Retained earns.(11,861)
Total liabs.2,641
 
  
 
 Interim Report

 
Interim Report   
 
Data Not Available
 
 
 
 
  
 
 Pro Forma Report

 
Pro Forma Report   
 
Data Not Available
 
 
 
 
  
 
 Quarterly Report

 
Quarterly Report Information   
 
Quarterly Revenue, US$
YearQuarterRevenue
  2008   1Nil
  2008   2Nil
  2007   1Nil
  2007   2Nil
  2007   3Nil
  2007   4Nil
  2007   Full Year Nil
  2006   Full Year Nil
 
 
Quarterly Net Income, US$
YearQuarterRevenue
  2008   1(740,000)
  2008   2(1,670,000)
  2007   1(830,000)
  2007   2(880,000)
  2007   3(930,000)
  2007   4(1,090,000)
 
 
Quarterly EPS, US$
YearQuarterRevenue
  2008   1(.04)
  2008   2(.09)
  2007   1(.05)
  2007   2(.05)
  2007   3(.05)
  2007   4(.06)
  2007   Full Year (.22)
  2006   Full Year (.17)
 
  
 
 Stock Data

 
 
Capitalization as of 06/30/2008:
 
 Authorized SharesOutstanding Shares
Common $0.001 par55,000,00020,120,791
 
LONG TERM DEBT: None.
 
Common $0.001 par
 
Stockholders:  03/17/2008, 73.
PRINCIPAL STOCKHOLDERS: April 24, 2008, Ghassan Nino owned or controlled 17.0% of the Common, Russell Cleveland 15.2%, Bruce Meyers 13.0%, and Arthur P. Bollon 9.6%.
 
Transfer Agent:  Continental Stock Transfer & Trust Co.   New York , NY
 
OTC Bulletin Board( Primary): HMBT
 
ExchangeYearHighLow
OTC Bulletin Board20072.30001.2000
OTC Bulletin Board20062.55001.2000
 
RECENT DIVIDENDS: Common $0.001 par: None.